EZZ Life Science cut its quarterly operating cash outflow sharply despite a 37.7% drop in customer receipts, as weaker Chinese e-commerce sales continued to weigh. EAORON skincare growth and a $9.16 million cash balance offer some support, but distributor collections and potential product returns remain unresolved.
